

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Alfred Berchielli, et al. :

APPLICATION NO.: To Be Assigned : Examiner: To Be Assigned

FILING DATE: Herewith : Group Art Unit: To Be Assigned

TITLE: Controlled-Release Pharmaceutical Formulations :

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.


The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: JUNE 25, 2003



Carl J. Goddard
Attorney for Applicant(s)
Reg. No. 39,203

Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 441-4902

EXPRESS MAIL NO. 510411467205

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>				ATTY. DOCKET NO. PC25096A				SERIAL NO. To Be Assigned			
				APPLICANT Alfred Berchielli, et al.							
				FILING DATE Herewith				GROUP To Be Assigned			

U.S. PATENT DOCUMENTS														
EXAMINER INITIAL	DOCUMENT NUMBER								DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	

FOREIGN PATENT DOCUMENTS														
DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	WO	0	1	•	2	1	6	•	10 May 2001	International	A61K	31/19		
	WO	0	1	4	7	5	0	0	5 July 01	International	A61K	9/36		

OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>													
			Torphy et al, Environ. Health Perspect, 102, Suppl. 10, pgs 79-84, 1994										
			Duplantier et al., J. Med. Chem, 39, pgs 120-125, 1996										
			Schneider et al, Pharmacol. Biochem. Behav., 50, pgs 211-217, 1995										
			Banner and Page, Br. J. Pharmacol, 114, pgs 93-98, 1995										
			Barnette, et al., J. Pharmacol, Exp. Ther., 273, pgs 674-679, 1995										
			Wright et al., Can. J. Physiol. Pharmacol, 75, pgs 1001-1008, 1997										
			Manabe et al., Eur. J. Pharmacol. 332, pgs 97-107, 1997										
			Ukita et al, J. Med Chem., 42, pgs 1088-1099, 1999										

EXAMINER	DATE CONSIDERED
-----------------	------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE

EXPRESS MAIL NO. 2U10411467205

INFORMATION DISCLOSURE CITATION LIST.DOT, 9/99